Effects of chronic metformin treatment on training adaptations in men and women with hyperglycemia: A prospective study
Alfonso Moreno‐Cabañas, Felix Morales‐Palomo, Laura Álvarez-Jiménez, Juan F. Ortega, Ricardo Mora‐Rodríguez
Abstract
Abstract Objective This study aimed to determine whether chronic metformin use interferes with the improvements in insulin resistance (IR) and cardiorespiratory fitness with aerobic training in people with hyperglycemia and metabolic syndrome (MetS). Methods A total of 63 middle‐aged (53 [7] years) individuals with MetS and obesity (BMI = 32.8 [4.5] kg/m 2 ) completed 16 weeks of supervised high‐intensity interval training (3 d/wk, 43 min/session). Participants were either taking metformin (EXER+MET; n = 29) or were free of any pharmacological treatment for their MetS factors (EXER; n = 34). Groups were similar in their initial cardiorespiratory fitness (maximal oxygen uptake [VO 2MAX ]), age, percentage of women, BMI, and MetS factors ( z score). The effects of exercise training on IR (homeostatic model assessment of insulin resistance [HOMA‐IR]), MetS z score, VO 2MAX , maximal fat oxidation during exercise, and maximal aerobic power output were measured. Results Fasting insulin and HOMA‐IR decreased similarly in both groups with training (EXER+MET: −4.3% and −10.6%; EXER: −5.3% and −14.5%; p value for time = 0.005). However, metformin use reduced VO 2MAX improvements by half (i.e., EXER+MET: 12.7%; EXER: 25.3%; p value for time × group = 0.012). Maximal fat oxidation during exercise increased similarly in both groups (EXER+MET: 20.7%; EXER: 25.3%; p value for time = 0.040). VO 2MAX gains were not associated with HOMA‐IR reductions (EXER+MET: r = −0.098; p = 0.580; EXER: r = −0.255; p = 0.182). Conclusions Metformin use was associated with attenuated VO 2MAX improvements but did not affect fasting IR reductions with aerobic training in individuals with hyperglycemia and high cardiovascular risk (i.e., MetS).